Morgan Stanley analyst Vikram Purohit raised the firm’s price target on Incyte to $77 from $76 and keeps an Equal Weight rating on the shares. The firm issued its biotechnology Q1 sector preview, stating that broadly for the group it does not "expect many surprises" given recently issued guidance. The firm sees investor focus being mainly on Q2 catalysts in the space.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INCY:
- Incyte management to meet with Oppenheimer
- Incyte downgraded to Sector Perform after physician survey at RBC Capital
- Incyte downgraded to Sector Perform from Outperform at RBC Capital
- Incyte granted orphan status for myelofibrosis treatment
- Incyte announces Japanese MHLW approval of Pemazyre
Questions or Comments about the article? Write to editor@tipranks.com